Jacobio Pharmaceuticals Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-30
RECRUITING7
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open Jacobio Pharmaceuticals Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| JAB-2485 (Aurora A inhibitor) NCT05490472 |
P1/2 | Recruiting | Solid Tumors; ER+ Breast Cancer | 102 | 2026-08 (+24 mo) |
| JAB-23E73 NCT06959615 |
P1/2 | Recruiting | Advanced Solid Tumor | 334 | 2026-12-31 (+12 mo) |
| JAB-30355 NCT06386146 |
P1/2 | Recruiting | Solid Tumors | 144 | 2027-01 |
| JAB-8263 NCT07684157 |
P2 | Recruiting | Rheumatoid Arthritis (RA) | 32 | 2027-06-30 |
| JAB-8263 NCT04686682 |
P1/2 | Recruiting | NSCLC; SCLC | 152 | 2028-01 (+72 mo) |
| JAB-23E73 NCT06973564 |
P1/2 | Recruiting | Advanced Solid Tumors | 344 | 2028-11 (+12 mo) |
| JAB-23E73 tablet,nab-paclitaxel,gemcitabine NCT07640295 |
P1/2 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 80 | 2029-12-31 |